An experimental drug for Alzheimer’s disease (AD) was shown to both slow cognitive decline and clear the sticky protein clumps in the brain that are a hallmark of the devastating illness – for some patients.
Researchers presented the latest findings Wednesday at the Alzheimer’s Association International Conference in Chicago, and while this drug is the first to affect both cognition and the neural tangles, the reception was mixed.
“This is the first large clinical trial to...
[Read More ...]
No comments:
Post a Comment